Successful treatment of persistent and severe SARS-CoV-2 infection in a high-risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies

Fernanda Braga Seganfredo; Ana Raquel Dias; Pedro R Santos; Marta Rebelo; Cristina João; Dina Mendes; Eduarda Carmo

doi:10.1002/ccr3.6548

Successful treatment of persistent and severe SARS-CoV-2 infection in a high-risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies

Clin Case Rep. 2022 Nov 15;10(11):e6548. doi: 10.1002/ccr3.6548. eCollection 2022 Nov.

Authors

Fernanda Braga Seganfredo¹, Ana Raquel Dias², Pedro R Santos³, Marta Rebelo³, Cristina João⁴, Dina Mendes⁵, Eduarda Carmo³

Affiliations

¹ Haematology Department Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG) Lisbon Portugal.
² Haematology Department Hospital do Divino Espírito Santo de Ponta Delgada Ponta Delgada Portugal.
³ Intensive Care Unit Centro Hospitalar Lisboa Ocidental - Hospital Egas Moniz Lisbon Portugal.
⁴ Haematology Department Fundação Champalimaud Lisbon Portugal.
⁵ Pharmaceutical Department Centro Hospitalar Lisboa Ocidental - Hospital Egas Moniz Lisbon Portugal.

Abstract

Patients with lymphoproliferative diseases are at an increased risk of an incomplete immune response following vaccination or SARS-CoV-2 infection and might develop persistent viral infection and severe COVID-19 disease. We present a case of successful treatment of persistent and mechanical-ventilation-requiring SARS-CoV-2 infection in a del17⁺ CLL patient using exogenous antibodies.

Keywords: COVID‐19; Casirivimab and Imdevimab; haemato‐oncological patients; immunity.

Publication types

Case Reports